The new once-daily oral tablet Exjade (Deferasirox, also known as ICL670) has been approved by FDA in the US.
Exjade is currently the only once daily iron chelator on the market. Its availability and approval for use in patients with chronic iron overload (from as young as 2 years of age) would revolutionise the management of illnesses like Beta Thalasaemia major.
Read the Novartis press release
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment